Dexamethasone for Non-small Cell Lung Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Wayne State University/Karmanos Cancer Institute, Detroit, MINon-small Cell Lung Cancer+3 MoreDexamethasone - Drug
Eligibility
Any Age
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing the effects of dexamethasone on lung cancer patients who have not responded to previous treatment. Imaging tests will be used to see if dexamethasone affects how tumors grow and respond to treatments.

Eligible Conditions
  • Non-small Cell Lung Cancer Stage IIIB
  • Non-Small Cell Lung Cancer
  • Stage IIIA Non-small Cell Lung Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: Day 6-9

Baseline
Tumor glucocorticoid receptor alpha expression
Baseline to day 9
Change in senescence markers in circulating tumor cells
Change in serum dexamethasone concentration
Change in tumor SUVmax assessed by 18F-FLT PET imaging
Day 6-9
Dexamethasone withdrawal as measured by changes in tumor FLT retention

Trial Safety

Safety Progress

1 of 3

Side Effects for

Ondansetron
2%Deep Vein Thrombosis
2%Cerebrospinal fluid leak
2%Fever
This histogram enumerates side effects from a completed 2013 Phase 4 trial (NCT01474915) in the Ondansetron ARM group. Side effects include: Deep Vein Thrombosis with 2%, Cerebrospinal fluid leak with 2%, Fever with 2%.

Trial Design

1 Treatment Group

Treatment (dexamethasone, 18F-FLT PET)
1 of 1

Experimental Treatment

10 Total Participants · 1 Treatment Group

Primary Treatment: Dexamethasone · No Placebo Group · N/A

Treatment (dexamethasone, 18F-FLT PET)Experimental Group · 4 Interventions: Dexamethasone, Device for PET, Positron Emission Tomography, Laboratory Biomarker Analysis · Intervention Types: Drug, Device, Procedure, Other
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dexamethasone
FDA approved
Positron Emission Tomography
2008
Completed Phase 2
~2800

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: day 6-9

Who is running the clinical trial?

Barbara Ann Karmanos Cancer InstituteLead Sponsor
160 Previous Clinical Trials
8,538 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,153 Previous Clinical Trials
41,162,298 Total Patients Enrolled
Anthony ShieldsPrincipal InvestigatorBarbara Ann Karmanos Cancer Institute
2 Previous Clinical Trials
8 Total Patients Enrolled

Eligibility Criteria

Age Any Age · All Participants · 11 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are expected to live for at least 4 more weeks.

Frequently Asked Questions

How many participants are authorized to join the trial?

"That is correct. Clinicaltrials.gov attests that this research project, which was originally posted in June 2016, still seeks participants. 10 people are needed to enrol at the single trial site for inclusion into the study." - Anonymous Online Contributor

Unverified Answer

Are there any available slots for this research study?

"Affirmative. Clinicaltrials.gov attests that this medical trial, which was published on June 1st 2016, is actively recruiting patients. The team aims to enroll 10 individuals across a single site." - Anonymous Online Contributor

Unverified Answer

Do other studies exist that delve into the use of Dexamethasone?

"Currently, there are 555 studies in progress concerning Dexamethasone with 143 of them being Phase 3 trials. There is a concentration of research based around Elk Grove Village, Illinois; however the drug's clinical testing spans across 18,660 different sites worldwide." - Anonymous Online Contributor

Unverified Answer

What conditions typically warrant Dexamethasone usage?

"Dexamethasone is typically administered for ophthalmic and sympathic purposes. It can also be utilized to address cases of branch retinal vein occlusion, macular edema, and other eye-related issues." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.